Stem Cell Therapeutics (SSS)

[BioSpecialist]

Big Partnership coming soon

REASONS TO INVEST IN STEM CELL THERAPEUTICS

• Lead program adressing a major unmet need with a large commercial potential
- Stroke is the leading cause of serious, long-term disability 1
- On average, a stroke occurs every 40 seconds 1
- Only treatments available: tPA (<4% of ischemic patients treated) and aspirin

• Current lack of effective treatment for reducing and repairing damage caused by stroke

• Shortened path to regulatory approval, decreased development risk and cost due to current FDA approval status of the drugs used in NTx®-265

• Attractive therapeutic window of NTx®-265 (within 24-48hours post stroke) and easy administration method (avoid the need for invasive brain surgery)

• Encouraging results from BETAS Phase IIa stroke trial demonstrated positive drug related effects on visual, motor and cognitive recovery in patients who suffered acute ischemic stroke.

• Additional indications being explored, traumatic brain injury (TBI) and multiple sclerosis (MS); also representing major unmet needs and large commercial potential

• Clinical programs with strong partnering potential

• Issued and pending patents protecting SCT's extensive intellectual property portfolio